EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Evidence for clinically significant prostate cancer, overdiagnosis, active surveillance, and PSA screening

Takeshi Takahashi

World Journal of Urology · 2024

DOI: 10.1007/s00345-024-04905-6 ↗

Kurz gefasst

Leserbrief in der Zeitschrift World Journal of Urology, 2024. Verfasst von Takeshi Takahashi. Beteiligte Einrichtung: Health and Welfare Bureau, Kitakyushu City Office, Jyonai 1-1, Kitakyushu, 803-8501, Japan. jazzy@kuhp.kyoto-u.ac.jp. Hauptthemen laut MEDLINE: Early Detection of Cancer, Prostatic Neoplasms. Die Arbeit nennt 9 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Early Detection of CancerProstatic NeoplasmsMaleHumansOverdiagnosisProstate-Specific AntigenMagnetic Resonance ImagingWatchful Waiting

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Health and Welfare Bureau, Kitakyushu City Office, Jyonai 1-1, Kitakyushu, 803-8501, Japan. jazzy@kuhp.kyoto-u.ac.jp.

Zitieren

APA

Takahashi, T. (2024). Evidence for clinically significant prostate cancer, overdiagnosis, active surveillance, and PSA screening. World Journal of Urology. https://doi.org/10.1007/s00345-024-04905-6

Vancouver

Takahashi T. Evidence for clinically significant prostate cancer, overdiagnosis, active surveillance, and PSA screening. World Journal of Urology. 2024. doi:10.1007/s00345-024-04905-6

BibTeX
@article{Takahashi2024,
  author = {Takahashi, Takeshi},
  title = {Evidence for clinically significant prostate cancer, overdiagnosis, active surveillance, and PSA screening},
  journal = {World Journal of Urology},
  year = {2024},
  doi = {10.1007/s00345-024-04905-6}
}
Kostenlos starten →